For Immediate Release

February 17, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc.(“Appili”), an anti-infective drug development company, announced today that it will be receiving $2,803,148 from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). This funding will enable Appili to take its first drug, ATI-1501 – a taste-masked, oral antibiotic that treats anaerobic infections like Clostridium difficile – through clinical trials to be ready for market approval.

“Having ACOA recognize the potential of our antibiotic reformulation to become a new weapon against anaerobic infections is outstanding,” said Kevin Sullivan, CEO of Appili Therapeutics. “This AIF funding supports our strategy to advance ATI-1501 into human clinical trials as soon as possible.”

Appili plans to take the antibiotic into clinical trials this year and is presently manufacturing the clinical batch of ATI-1501 to good manufacturing practices (GMP), the standard required by the Health Canada and the U.S. Food and Drug Administration (FDA).

ATI-1501 is a reformulation of metronidazole, a front-line treatment for anaerobic bacterial infections, including C. difficile.  Over 10 million metronidazole prescriptions are issued in the U.S. annually.

The bitter taste of the metronidazole tablets results in poor patient compliance, which leads to the spread of infections and recurrent infections within the patients.  In particular, reluctance to complete the prescribed course of antibiotics is highly problematic among children and the elderly with swallowing issues, who must crush and re-suspend tablets to ingest the metronidazole.

ATI-1501 has been optimized to improve palatability, which should significantly reduce issues with non-compliance. Once ingested, ATI-1501 kills anaerobic bacteria by interfering with their DNA, leading to bacterial cell death and clears up the infection.

About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit


Media Relations Contact: Investor Relations Contact:
Jennifer Cameron Kevin Sullivan, CEO, Appili Therapeutics
T: 902-209-4704 E:


See original release here

HALIFAX, Nova Scotia – February 14, 2017 — Kinduct Technologies, a data and analytics software provider, and Athletigen Technologies Inc., a leader in proprietary human performance insights and genetic analytics provider, today announced that Kinduct’s software platform will soon incorporate Athletigen’s genetic insights.

“The partnership with Kinduct is an exciting opportunity, with both companies focused on pushing the limits of human performance, ” says Athletigen CEO, Dr. Jeremy Koenig. “Clients will now have access to genetic markers combined with performance data, biometric scores and subjective inputs to provide a comprehensive view of the athlete to help understand and improve their in-game performance.”

Athletigen’s proprietary platform analyzes an athlete’s DNA to empower coaches and athletes with actionable insights to inform peak performance in training and competition. The Kinduct platform enables organizations to analyze athlete data collected from different sources and then use those insights to inform decisions and drive continuous improvement in human performance.

Koenig added, “Each athlete is made for greatness, and we are one step in the journey to harnessing their maximum potential.”

“Athletigen analyses genetic markers that help athletes understand where their performance strengths and weaknesses truly lie,” says Dr. Travis McDonough, Kinduct Founder and CEO. “The partnership with Athletigen and the integration of their genetic insights into Kinduct’s platform will create a powerful tool for assessing an athlete’s condition and defining the optimal training and recovery programs.”

Kinduct’s technology platform, currently used by teams in the NHL, MLB, NFL, NBA, MLS, and NCAA allows for a two-way information exchange between coaches and athletes. Their Athlete Management System (AMS) gives teams the ability to collect, analyze, and act upon a wide range of player performance data and content such as training results, sleep schedules, maximum acceleration, deceleration, and heart rate. All of the information captured or calculated within the Kinduct platform supports informed decisions on personalized training and injury recovery programs for every athlete. This new partnership with Athletigen adds genetics as an important new layer of data.

“We see this combination of performance data and genetics as an important step in maximising player performance while reducing injury risk,” says McDonough. “Our clients can gain access to each athlete’s genetic foundation to better explain the data we capture.”


About Athletigen

Athletigen is a leader in proprietary human performance insights and genetic analytics. In 2016, Athletigen launched Iris™, the first of its kind, a personalized performance genomics app suite that merges an athlete’s genetic predispositions with daily monitoring data, empowering coaches and athletes with actionable insights. The evolution of our product is driven by intense user research conducted with world class, Olympic and Paralympic athletes. Through genomic innovation with strategic partners, Athletigen works to deliver the most advanced research findings in human performance to its customers.

About Kinduct

Kinduct is a leading data and analytics software provider. Kinduct’s highly secure, cloud-based platform allows human performance and sports organizations to spend less time managing their data and more time using it to inform decisions, promote constant improvement and produce exceptional results. Kinduct’s Athlete Management System is integrated with the best and brightest companies in the wearables, assessment and data collection sector. Kinduct is the software provider of choice for many professional and elite level sport organizations in the NFL, NBA, MLB, NHL, MLS and other professional or elite leagues. Kinduct’s investors include Intel Capital, CFFI Ventures Inc., and Elysian Park Ventures.

Media Contacts:


Bryce Crosby
T: 902.440.2957


Sean Williams
T: 902.220.5945

See full story by Sara Ericsson in Queens County Advance

CORNWALLIS, N.S. – Nova Scotia’s provincial government has announced funding for internships in research and innovation aimed at creating work opportunities for Nova Scotia students and companies.

It was announced Feb. 6 at Acadian Seaplants in Cornwallis that $705,000 in funding will create 170 internships over the next three years. Sixty of these internships will take place at Acadian Seaplants, in partnership with Dalhousie University and the Mitacs Accelerate Program.

The company, which processes seaweed to create products for numerous agricultural and chemical uses, has a long history of partnering with researchers to deliver cutting-edge products.

President and CEO JP Deveau said his company “sees research as a way of life,” and that partnerships between industry, government and research institutions are key to “working together to create technologies we can export around the world.”

Kelly Regan, Minister of Labour and Advanced Education, also attended Monday’s event, speaking about creating opportunities for recent university graduates.

“Hiring people that we invest in early… will help create a better Nova Scotia,” she said.

Original Press Release

University Health Network (UHN) in Toronto to Launch Triple-Combination Study Evaluating the Potential for Enhanced Anti-Cancer Activity of Currently Marketed Checkpoint Inhibitor When Combined with DPX-Survivac

 Halifax, Nova Scotia; February 6, 2017 – Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage immuno-oncology company, today announced that the UHN’s Princess Margaret Cancer Centre (PM) will conduct a Phase 2 clinical trial to evaluate the use of a combination of immunotherapies from Immunovaccine and Merck (known as MSD outside the United States and Canada).

Clinical investigators will assess the safety and efficacy of Immunovaccine’s DPX-Survivac cancer vaccine candidate in combination with Merck’s checkpoint inhibitor Pembrolizumab in patients with recurrent, platinum-resistant ovarian cancer. Study participants will also receive metronomic cyclophosphamide, which is a low-dose regimen with immuno-modulating effects. PM listed the trial on and expects to initiate active enrollment following completion of the contract between Immunovaccine and UHN, and pending regulatory clearance from Health Canada.

“Ovarian cancer is a main focus for Immunovaccine as we continue to develop DPX-Survivac,” said Frederic Ors, Immunovaccine’s Chief Executive Officer.  “Combination therapies — particularly those with anti-PD-1 activity — are emerging as increasingly promising approaches for hard-to-treat cancers. We believe that the robust immunogenic and safety clinical profile for DPX-Survivac, along with its unique complementary activity to anti-PD-1 agents, which may boost their response rates, position our immuno-oncology candidate as an optimal co-therapy in this disease area.”

The non-randomized, open-label trial is designed to evaluate the potential anti-tumor activity of the combination of Pembrolizumab, DPX-Survivac, and low-dose cyclophosphamide. It is expected to enroll 42 subjects with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. The study’s primary objective is to assess overall response rate (ORR). Secondary study objectives include progression free survival (PFS) rate, overall survival (OS) rate, and potential side effects, over a five-year period.

 Amit M. Oza, Bsc (Hons), MBBS (Lon), MD (Lon), FRCPC, FRCP, Senior Staff Physician and Associate Professor of Medicine at PM is the lead investigator. Merck is funding this study and contributing materials. Immunovaccine is also contributing its product candidate as well as a related portion of analytical assays.

“Ovarian cancer is among the most challenging cancers to treat, as it is associated with poor response rates to currently available medical interventions,” said Dr. Oza. “To support the tens of thousands of women battling this disease, we need to develop new and novel approaches. With this trial, we have the opportunity to explore a novel combination of promising immunotherapies.”

DPX-Survivac is Immunovaccine’s lead immuno-oncology candidate, generated by its novel proprietary DepoVax™ adjuvanting technology platform. The DPX-Survivac target, survivin, is present in more than 20 types of solid tumor and hematologic cancers. It is involved in multiple critical pathways of cancer cell growth and survival. Prior results from a Phase 1/1b study indicated that DPX-Survivac combined with a low dose of cyclophosphamide was highly immunogenic in individuals with high-risk ovarian cancer, inducing survivin- specific T cell immune responses in most trial participants.

The company has shown in other studies that a combination immunotherapy using a DepoVax™-based vaccine could enhance the anti-tumor effects of a PD-1 blockade. Even tumors previously non-responsive to treatment with anti-PD-1 agents alone exhibited controlled cancer growth when combined with Immunovaccine’s DepoVax™-based compound.

In addition to this Phase 2 trial, Immunovaccine is conducting a Phase 1b trial with Incyte Corporation to evaluate the triple combination of DPX-Survivac with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, Epacadostat (INCB24360), and low-dose oral cyclophosphamide in patients with platinum sensitive or resistant ovarian cancer. Immunovaccine expects to announce top-line interim results for this Phase 1b trial by the end of March 2017.

About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. The National Cancer Institute (NCI) has recognized survivin as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in multiple cancer types in addition to ovarian cancer, including breast, colon and lung cancers. Survivin plays an essential role in antagonizing cell death, supporting tumor-associated angiogenesis, and promoting resistance to anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in a higher percentage of tumors than other TAA’s.

The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides. This targeted therapy attempts to use the immune system to search actively and specifically for tumor cells and destroy them. Survivin-specific T-cells have been shown to target and kill survivin-expressing cancer cells while sparing normal cells.

DPX-Survivac received Fast Track designation by the FDA as maintenance therapy in individuals with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival. The FDA also granted orphan drug status to DPX-Survivac for the treatment of ovarian cancer. This designation is valid for all applications of DPX-Survivac in ovarian cancer without restriction to a specific stage of disease.


About the Princess Margaret Cancer Centre of the Toronto Hospital

 The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to or

About Immunovaccine

Immunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented delivery agent that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer, as well as a Phase 2 study in recurrent lymphoma. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and currently has clinical projects ongoing to assess the potential of DepoVax™ to address malaria and the Zika virus. Connect at


Immunovaccine Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.


 Contacts for Immunovaccine:
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E:
Frederic Ors, Chief Executive Officer
T: (902) 492-1819 E: 

See original release

January 6, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that Stephen Nicolle has been appointed to its Board of Directors. A seasoned executive, Mr. Nicolle has led companies to deliver innovative customer value and returned over $100 million to their investors.

“When it comes to leading venture-backed companies, Mr. Nicolle brings unparalleled business expertise and vision that will be instrumental as we grow and develop our pipeline of anti-infective products,” said Kevin Sullivan, CEO of Appili Therapeutics.

“I am attracted by Appili’s strategic approach of acquiring and developing early stage and late stage products which uniquely address the global demand for new antibiotic treatments to combat bacterial resistance,” said Stephen Nicolle, board director of Appili Therapeutics.  “I am honoured to join Appili’s board and look forward to making a contribution to this ambitious and exciting start-up company.”

Mr. Nicolle has 20 years of experience leading companies and growing shareholder value.  He is currently president of Cape Bear Advisors where he consults and holds numerous board positions, including vice chair of the start-up accelerator Propel ICT. Mr. Nicolle is the former CEO of leading healthcare technology company, STI Technologies, where he negotiated agreements with top pharmaceutical companies resulting in an increase in revenue of 500 per cent.  Before STI Technologies Mr. Nicolle spent 10 years leading venture-backed technology companies, including: CEO of Tatara Systems, CEO of Sigma Systems, COO at March Networks, and President of Nortel’s Service Provider eBusiness Solutions Group. He is a graduate of Western University with an honours degree in computer science.

Mr. Sullivan makes this announcement as he heads to San Francisco, where the life science industry’s largest investor conference, the JP Morgan Healthcare conference, is being held.

About Appili Therapeutics Inc.

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The Company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501, a taste-masked treatment for anaerobic infections, including Clostridium difficile, has been granted orphan drug status by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit

Media Relations Contact:

Jennifer Cameron

T: 902-209-4704


See original release here

December 21, 2016 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today it raised $2,151,000 in its over-subscribed private placement financing. Participants in this capital raise included current Appili investors such as Innovacorp, as well as new individual and institutional investors. Proceeds from the financing will be used to advance its lead product candidate, a taste-masked antibiotic designed to treat anaerobic infections like Clostridium difficile, into clinical trials. In addition, the Company will advance the development of a novel class of antibiotics targeting drug-resistant Gram-negative bacteria and evaluate opportunities to add high potential anti-infective programs to its pipeline.

“We appreciate the support and confidence our investors have in our strategy to build a pipeline of products that fit with our balanced-risk portfolio approach,” said Kevin Sullivan, CEO of Appili Therapeutics. “We continue to seek new programs that complement this balanced-risk approach with a mix of near-term revenue programs along with early stage programs that have the potential to fundamentally change how we treat infectious disease.”

“In a very short period of time, Appili has made significant progress with their strategy to identify and develop improved anti-infective therapies, and we look forward to supporting their upcoming clinical trial,” said Dr. Lidija Marušić, life sciences investment manager at Innovacorp, Nova Scotia’s early stage venture capital organization, and member of Appili’s Board of Directors.

“We are thrilled by the strong investor interest in this financing, which validates Appili’s strategy, science and development programs,” said Brian Bloom, president of Bloom Burton & Co., a healthcare-specialized investment bank, and chair of Appili’s Board of Directors.

About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The Company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501, a taste-masked treatment for anaerobic infections, has been granted orphan drug status by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae. These drug-resistant infections have been identified by the U.S. Center for Disease Control (CDC) as posing the highest threat to human health. For more information visit


Media Relations Contact: Investor Relations Contact:
Jennifer Cameron Kevin Sullivan, CEO, Appili Therapeutics
T: 902-209-4704 E:

See full original release here

TruLeaf Closes $8.5-million Round of Financing
Former executive of Scotiabank joins TruLeaf board of directors


TORONTO, ON/BIBLE HILL, NS, December 7, 2016 – TruLeaf Sustainable Agriculture Ltd. (TruLeaf), the indoor, multi-level farming company from Bible Hill, Nova Scotia has closed an $8.5-million equity-finance round. This funding will enable the company to continue its mission of becoming a global leader in vertical farming technology. TruLeaf develops sustainable farming systems that can be built anywhere that enable fresh, nutrient-dense, pesticide-free produce to be grown locally all year round.

Mike Durland, Former CEO and Group Head of Scotiabank’s Global Banking and Markets division led this funding round along with a small group of strategic investors from Toronto. In addition, Mr. Durland and Neil Murdoch, Former CEO Connor, Clark & Lunn Capital Markets, will become members of TruLeaf’s Board of Directors.

“This new round of financing and the additions to our board will help us to expand the breadth of our product offerings and increase the number of markets that we serve,” said Gregg Curwin, President & CEO, TruLeaf. “Mike and Neil bring a high level of business acumen and strategic expertise that will help us scale our business.”

TruLeaf is positioned to meet the growing appetite for local food in Canada that has arisen in the last 10 years, by scaling its GoodLeaf Farms consumer brand. A 2013 BMO Food Survey found that Canadians buy locally grown vegetables above all other products. Ninety-seven per cent of those surveyed said they bought local because the food is fresh and tastes better.

TruLeaf is seeking to become a leader in sustainable agriculture through the use of vertical farming. Vertical farming combines proven hydroponic technology with advancements in LED lighting and environmental control to allow year-round propagation and production of plants indoors, inside stackable levels. Vertical farming is nearly ten times more efficient than traditional agriculture and is more productive, takes up less land and uses dramatically less water.

“There are a number of important macro forces which position TruLeaf for success in the coming years,” said Mr. Durland. “Food scarcity, water challenges, the increasing demand for pesticide-free foods, and the environmental impact of large-scale farming, all mean that new ways of growing and distributing foods will be key for feeding the world. We want TruLeaf to be a company that achieves a triple-bottom line by creating sustainable – and ultimately carbon neutral – food production, delivering nutrient-rich plants to communities that may not otherwise have access to them, and achieving a strong return for investors and stakeholders. We want to grow the best products for
consumers in Canada.”

A native Nova Scotian and Saint Mary’s University graduate, Mr. Durland recently retired from his executive post at Scotiabank to focus his efforts on fostering growth and investment in innovative companies across the country. Recently, he provided important funding for Saint Mary’s University’s Masters of Technology, Entrepreneurship & Innovation program, which supports an innovation competition held in Halifax each year. Mr. Durland’s interest and passion for TruLeaf was spawned out of his desire to invest in the local Nova Scotia economy.

Founded in 2011, and located in Bible Hill, Nova Scotia, TruLeaf has developed an indoor farming system that grows fresh plants for food and medicines anywhere in the world, regardless of environment, 365 days a year. The system integrates growing technologies in a controlled environment to grow high quality, predictable yield, and clean plants with innovative and efficient technologies.

Media Contact:
Holly Thornton
Account Manager, PUBLIC Inc.
P: 647 642 6846

To see original article, click here

For Immediate Release

Halifax, NS -Windsor based, BioMedica Diagnostics (BMD) made the announcement today that it has purchases the specialty coagulation business and product line from Sekisui Diagnostics (SDG).

The agreement includes all aspects of the business worldwide, with the exception of Europe, Middle East, and Africa, where SDGmbH, a Sekisui Diagnostics subsidiary, will continue to distribute and support the products in partnership with BMD. In conjunction with this agreement, BMD will also acquire the American Diagnostica trademark.

“This is great news, not only for BioMedica Diagnostics but for the entire life sciences sector,” Said Scott Moffitt, Managing Director at BioNova – the association leading the development of the life sciences sector in Nova Scotia. ” This acquisition is proof of our global competitiveness and our capabilities to build high growth life sciences companies right here in Nova Scotia.”

The agreement closed as of December 1st, 2016 and from this time forward BMD will be responsible for the operation of the business.


About BioMedica Diagnostics

Established in 1999, we are a diagnostics company with a focus on providing customized diagnostic solutions in human and animal health. The acquisition of these assets is a natural fit to further solidify our foundation in thrombosis and haemostasis and expand our reach in specialty coagulation.


Contact info

BioMedica Diagnostics

Nadine Williams



Jessica Gillis, Communications Officer



See original article here

Ottawa, December 1, 2016 – Innovative Medicines Canada is pleased to announce the appointment of Pamela Fralick as its new President, effective immediately.

Ms. Fralick comes to Innovative Medicines Canada as a proven healthcare leader, with a wealth of experience advancing critical healthcare initiatives and a deep understanding of public policy and organizational management.

“We are extremely pleased to have Ms. Fralick lead our association at such an important time both for the country’s innovative pharmaceutical industry and in the evolution of the Canadian healthcare system,” said Michael Tremblay, Chair of the Board of Directors, Innovative Medicines Canada and President of Astellas Pharma Canada, Inc. “Ms. Fralick has had a unique opportunity to participate in many aspects of Canada’s healthcare system, and throughout her career has demonstrated a commitment to improving the lives and health outcomes of Canadians. We believe she is the right person to lead Innovative Medicines Canada as we work with our partners to build a more healthcare sustainable system.”

As the former President and CEO of the Canadian Cancer Society, Ms. Fralick led a three-year process of intense transformation, resulting in significant improvements to the operational and governance structures of the organization. Prior to this, she spent five years as president and CEO of the Canadian Healthcare Association, a federation of provincial and territorial hospital and health organizations, as well as six years as CEO of the Canadian Physiotherapy Association. She was chair of the Health Action Lobby (HEAL) and co-chair of the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit.

“As a healthcare professional dedicated to helping Canadians live longer and healthier lives, I am honoured  to represent a national association whose members are responsible for developing innovative medicines and vaccines that materially improve the quality of life for so many Canadians,” said Pamela Fralick, President, Innovative Medicines Canada. “I look forward to collaborating with all of our partners across the country to improve access to these lifesaving medicines.”

Ms. Fralick has also been a senior volunteer with the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the boards of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair).

Ms. Fralick takes over from Elaine Campbell, who has been Interim President of Innovative Medicines Canada since June.


For further information:

Sarah Dion-Marquis

Media Relations

Telephone: 613-769-6510



About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.


To see original article, click here

For Immediate Release

HALIFAX, Dec 1, 2016 – Tom Lynch, Chair of Precision BioLogic’s Board of Directors, is pleased to announce the appointment of Paul Empey as President and CEO of the company.

Most recently Precision BioLogic’s Executive Vice President, Empey joined the organization in 2015, bringing with him more than 30 years of experience in senior and executive positions at several successful organizations including Ocean Nutrition Canada, which is now part of Royal DSM.

Hailing originally from Boston, Empey has been helping Canadian organizations reach their potential for more than two decades. As President and CEO, he will play an active role in Precision BioLogic’s strategic direction, working closely with the board and senior management team.

Empey is pleased to have the opportunity to further develop Precision BioLogic.

“2016 saw a lot of exciting activity, including our humanitarian aid donation to the University Teaching Hospital in Yaoundé, Cameroon. Our donation made Precision BioLogic the first diagnostics company to support the World Federation of Hemophilia’s efforts to close the gap in care between those with bleeding disorders who receive proper diagnosis and treatment and those who do not,” he explains. “2017 promises to be equally exciting as we celebrate the 25th anniversary of cryocheck™, our line of frozen diagnostic products for coagulation testing,” he adds.

About Precision BioLogic

Precision BioLogic is a privately-held company that develops, manufactures and markets specialized products used by medical professionals and researchers around the globe to diagnose coagulation disorders and develop new products to improve patient outcomes. For more information, visit

– 30 –

 For more information, contact:

Elaine Benoit, Precision BioLogic
902.430.7795 Ÿ

2015 © Copyright - Bionova